Clinical trial / 2007
Salba supplementation reduced blood pressure and inflammatory markers in well-controlled type 2 diabetes.
In a randomized crossover trial, 20 adults with type 2 diabetes consumed 37 +/- 4 g/day of Salba or wheat bran for 12 weeks. Compared with wheat bran, Salba reduced systolic blood pressure by 6.3 +/- 4 mmHg (P < 0.001), high-sensitivity C-reactive protein by 40 +/- 1.6% (P = 0.04), and vonWillebrand factor by 21 +/- 0.3% (P = 0.03). Body weight and kidney function remained unchanged.
- Study type
- Randomized crossover trial
- Who was studied
- 20 adults with type 2 diabetes, Canada
- What was measured
- cardiovascular risk factors, blood pressure, hs-CRP, and vWF
THE PAPER
Supplementation of conventional therapy with the novel grain Salba (Salvia hispanica L.) improves major and emerging cardiovascular risk factors in type 2 diabetes: results of a randomized controlled trial.
Vuksan V, Whitham D, Sievenpiper JL, Jenkins AL, Rogovik AL, Bazinet RP, Vidgen E, Hanna A. Diabetes Care, 2007.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.